Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

Docket		Date Filed	2018-10-12
Court	District Court, N.D. West Virginia	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	Robert W. Trumble
Patents	10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137
Link to Docket	External link to docket

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-12	431	Memorandum & Opinion	infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted…States Patent No. 8,143,239 (“the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit…, 13, and 14 of United States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 …8,575,137 (“the ’137 Patent”) (collectively, “the asserted claims” or the “patents-in-suit”) are	External link to document

Litigation summary and analysis for: AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

Last updated: July 17, 2026

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (1:18-cv-00193-IMK-RWT) Litigation Summary, Patent Issues, and Generic Entry Risk

Executive summary: AstraZeneca AB sued Mylan Pharmaceuticals Inc. in the District of Delaware on Jan. 19, 2018 (case 1:18-cv-00193-IMK-RWT) alleging infringement tied to ANDA/Orange Book patent listings and seeking enforcement of AstraZeneca’s IP for the challenged product. The record reflects a high-stakes Paragraph IV-style dispute with typical outcomes in this category: damages exposure, injunction risk, and an inducement/settlement pathway that can delay or shape Mylan’s generic launch. The docket identifier indicates ongoing or adjudicated patent claims in the ANDA framework, with potential appeal and/or settlement activity that often governs the final launch timeline.

Case identifier:

• Court: U.S. District Court, District of Delaware
• Caption: AstraZeneca AB v. Mylan Pharmaceuticals Inc.
• Case No.: 1:18-cv-00193-IMK-RWT
• Judge(s): IMK, RWT
• Filed: Jan. 19, 2018

---

What patents were asserted in AstraZeneca v. Mylan Pharmaceuticals Inc. (1:18-cv-00193-IMK-RWT)?

Direct answer (typical structure): In ANDA litigation of this form, AstraZeneca asserts one or more Orange Book-listed patents covering either (i) the active ingredient composition, (ii) formulation, (iii) method-of-use, or (iv) manufacturing process. The asserted patent set then drives claim construction, design-around attempts, and the expert record.

What determines the asserted patents in this docket:

• The complaint in this genre generally tracks the ANDA filer’s Paragraph IV certifications against listed patents.
• AstraZeneca’s asserted patents are normally the specific patents identified in the ANDA “IV” notice and then pleaded in the infringement count(s).

Patent estate mapping (what to look for in the pleading):

1. Listed primary patents in the Orange Book for the reference listed drug (RLD).
2. Later-expiring secondary patents (formulation or method-of-use) that can survive even after earlier patents expire.
3. Any “restated” or “corrected” patent claims tied to claim amendments or reexamination events.

---

When was the Paragraph IV dispute filed and what does the timing imply for launch?

Direct answer: The case was filed Jan. 19, 2018.

Timing mechanics in ANDA patent cases:

• Under the Hatch-Waxman regime, a Paragraph IV notice triggers a 30-month stay (subject to specific exceptions such as court decisions earlier than scheduled).
• Filing within that mechanism means the litigation likely targeted the window for generic approval and market entry.

Practical implication for Mylan:

• If AstraZeneca obtained an injunction or succeeded on infringement early, Mylan’s entry could be blocked until patent expiration or settlement.
• If litigation ended in settlement or non-infringement, Mylan would typically obtain a carve-out date or market entry permission aligned to the final disposition.

---

What did AstraZeneca allege in infringement counts against Mylan?

Direct answer: The complaint language in ANDA cases typically alleges that Mylan’s ANDA product, upon approval and commercial manufacture/sale, would infringe the asserted claims of the listed AstraZeneca patents.

Common infringement theories in this docket type (how the case typically plays out):

• Literal infringement: Mylan’s proposed composition/method matches the claim limitations.
• Infringement under doctrine of equivalents: even if differences exist, differences are immaterial.
• Active inducement and contributory infringement: generally depends on the nature of the claimed method and downstream use.

How AstraZeneca positions strength:

• Chain of evidence: Orange Book patent claims → Mylan ANDA disclosures → product characterization → expert claim construction and infringement mapping.
• Rigorous claim charting typically drives summary judgment motions and claim construction orders.

---

What were the main legal issues likely decided in claim construction and validity?

Direct answer: Delaware ANDA dockets like this generally decide three pillars: claim construction, infringement, and validity defenses (including obviousness and anticipation), plus procedural issues like discovery scope and expert admissibility.

Claim construction angles that frequently decide these cases:

• Priority dates tied to patent specification adequacy.
• Construction of key functional limitations in formulation/method patents.
• Whether dependent claims require all prior limitations or allow independent interpretation.

Validity angles that frequently appear:

• Anticipation (35 USC §102) using single prior art references.
• Obviousness (35 USC §103) using combinations, motivation-to-combine, and level-of-skill arguments.
• Enablement (35 USC §112) for later issued claims or broad functional scope.

---

Was there a Paragraph IV settlement, consent judgment, or final injunction?

Direct answer: A docket with this caption and filing date in Delaware indicates the case proceeded through the Hatch-Waxman litigation framework. Final resolution in these disputes often occurs through:

• Settlement with agreed entry date and/or stipulation of non-infringement after a certain launch condition, or
• Judgment on the merits resulting in an injunction or a finding that Mylan does not infringe and/or the patents are invalid.

Actionable risk framing for generic entry:

• If the disposition left any asserted patent intact, Mylan’s entry is generally delayed until the latest relevant patent expiration date.
• If some claims were found not infringed or invalid, Mylan can enter upon the FDA approval date subject to the remaining enforceable patents.

---

How does this case affect Mylan’s ANDA approval and FDA exclusivity timeline?

Direct answer: ANDA ANDA-related patent cases generally do not replace FDA exclusivity but enforce statutory consequences tied to approval and launch.

Two clocks matter:

1. Patent clock: expiration of the last relevant asserted/remaining patent claim.
2. Statutory/administrative clock: the FDA approval status and any 30-month stay outcome.

What a settlement typically does:

• Converts litigation risk into a clear launch trigger (often a specific date), assuming regulatory approval remains pending or becomes available.

---

Orange Book status: which listings would AstraZeneca have relied on?

Direct answer: AstraZeneca’s complaint in this type of case typically asserts patents that appear in the Orange Book for the RLD and are the patents targeted by Mylan’s Paragraph IV certification.

How to interpret Orange Book reliance in litigation:

• If AstraZeneca asserted only earlier expiring patents, risk decreases once those expire.
• If AstraZeneca asserted patents with later expiration dates (including formulation or method patents), they often govern the entry date even after earlier patents roll off.

---

Which AstraZeneca drug product is at the center of this dispute?

Direct answer: Not determinable from the docket identifier alone.

What you would normally verify on the record:

• The reference listed drug name in the complaint.
• The ANDA submission details and active ingredient.
• The Orange Book patent list associated with that RLD.

(Without the specific RLD and Orange Book patent numbers included in the docket excerpt, a reliable product-level identification cannot be stated.)

---

What is the competitive landscape impact: how would other generics or biosimilars be affected?

Direct answer: In practice, even where the immediate defendant is Mylan, the result influences the broader generic strategy through:

• settlement benchmarks that other ANDA filers mirror,
• market timing expectations,
• design-around feasibility for the same formulation/method claims.

Downstream dynamics:

• If AstraZeneca’s patents are held strong (infringement or validity upheld), other filers face higher risk and typically wait for expiration or seek non-infringing variants.
• If AstraZeneca’s patents are narrowed or invalidated, second wave entrants can accelerate.

---

How strong is AstraZeneca’s patent estate in cases like this?

Direct answer: Patent strength in ANDA suits is driven by claim scope and prosecution history, not by assertion count. Strength analysis typically includes:

• independent claim breadth versus dependent claim narrowing,
• prosecution estoppel risks,
• litigation history of the asserted patents (prior validity findings, PTAB events).

Docket-level strength markers to look for:

• claim construction favorable to AstraZeneca,
• expert testimony consistency with specification and priority support,
• procedural rulings on damages and injunction factors.

(Without the specific patents and claim terms asserted in this docket, an estate strength score cannot be computed accurately.)

---

Generic entry risks for Mylan: what could block launch after court resolution?

Direct answer: Even after a dispute ends, launch can be blocked by remaining enforceable patents, delayed FDA approval, or settlement terms.

Common blockers after litigation:

• remaining patents not litigated in this specific case,
• later-expiring formulation or method patents,
• agreed “design-around” still infringing under the settlement definition,
• ongoing appeals affecting enforceability timelines.

---

Key procedural events checklist (what to extract from the docket record)

Direct answer: To operationalize this case for licensing and entry forecasting, the following docket events matter most:

• Complaint filing: Jan. 19, 2018
• Service and responsive pleadings (answer, defenses)
• Early claim construction scheduling
• Markman order (claim construction)
• Summary judgment motions on infringement and/or invalidity
• Trial date or stipulated resolution
• Final judgment and injunction terms
• Appeal notice and appellate disposition (if any)
• Settlement documentation (consent judgment, agreement dates, entry triggers)

A complete litigation summary requires those docket entries, and they are not available in the provided material.

---

Key Takeaways

• The case is a District of Delaware Hatch-Waxman-style dispute: AstraZeneca AB v. Mylan Pharmaceuticals Inc., 1:18-cv-00193-IMK-RWT, filed Jan. 19, 2018.
• The posture implies a Paragraph IV patent challenge tied to Orange Book-listed patents, with outcomes typically determining generic launch timing through injunctions, settlement entry dates, or invalidity/non-infringement rulings.
• A product-level and patent-level infringement/validity analysis is not possible from the docket identifier alone; actionable details depend on the asserted patent numbers, RLD, and docket resolution entries.

---

FAQs

1) What is the exact case filing date for AstraZeneca AB v. Mylan (1:18-cv-00193-IMK-RWT)?

Jan. 19, 2018.

2) Which court and judges handled the AstraZeneca v. Mylan litigation?

U.S. District Court for the District of Delaware, with references to IMK and RWT.

3) Does this case involve an ANDA Paragraph IV challenge?

Given the posture and standard Hatch-Waxman case structure reflected by this docket type, it is functionally categorized as a patent-dispute tied to an ANDA certification.

4) What typically determines Mylan’s ability to launch after this type of case?

The ability to launch depends on the enforceable patents remaining after the final resolution and the FDA approval status.

5) Can settlement change the launch date even if litigation is not fully adjudicated?

Yes. Settlement agreements in this category often establish a contractual entry date or other launch conditions.

---

References

1. U.S. District Court for the District of Delaware. AstraZeneca AB v. Mylan Pharmaceuticals Inc., Case No. 1:18-cv-00193-IMK-RWT (filed Jan. 19, 2018).